Skip to content

Author

R. Madan

We have 3 of 34 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Progression to castration-resistance and metastatic disease following androgen deprivation therapy for biochemical recurrence after prostate cancer surgery.

In this large national cohort of men with biochemical recurrence after surgery, most did not develop metastatic disease during nearly 10 years of follow up and one in four patients were treated with androgen deprivation therapy.

G. Raster, David A. Elliott, Ellen Hu et al. · 0 citations
Open access 2026

Highlighting the NCI’s working group on biochemically recurrent prostate cancer for clinical trial considerations

. Biochemically recurrent prostate cancer (BCR) represents a common clinical challenge following definitive local therapy. While traditionally defined by rising prostate-specific antigen (PSA) levels in the absence of metastatic disease on conventional imaging, the advent of prostate-specific membrane antigen (PSMA) PE...

J. Aragon-Ching, R. Madan · 0 citations
Sep 2026

Quantitative Thresholds on 18F-DCFPyL PET for Determining Malignancy in Prostate Cancer with Pathologic Correlation.

In this article, we assess histologically validated quantitative parameters on 18F-piflufolastat (18F-DCFPyL) prostate-specific membrane antigen (PSMA) PET and identify thresholds for differentiating malignant prostate cancer from benign tissue. Methods: In this multicenter retrospective study, men with prostate cancer...

L. Lindenberg, Erich P. Huang, G. Ulaner et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.